Beyond Earnings, the First Year of 'China-Free' Benefits... Samsung Biologics Holds the Key to Global Supply Chain Restructuring

Securities Firms Set Target Price at 2.2 Million Won

Samsung Biologics now stands at the center of the global bio supply chain restructuring, drawing intense attention from investors regarding how this will impact its stock price and valuation this year. The securities industry believes that changes in the external environment, epitomized by the U.S. 'Biosecure Act,' will serve as a key rationale for granting a 'valuation premium' to Samsung Biologics, going beyond simply resolving uncertainties.

According to the financial investment industry on January 26, major securities firms such as Samsung Securities, Kiwoom Securities, and NH Investment & Securities have recently assigned a 'BUY' investment rating and a target price of 2.2 million won to Samsung Biologics. This suggests an upside potential of more than 22% compared to the closing price of 1,802,000 won on January 24.

The securities industry identifies the driving force behind Samsung Biologics' stock price growth as 'highly visible growth.' Keunhee Seo, a researcher at Samsung Securities, evaluated that "profitability has been strengthened since the transition to a pure contract development and manufacturing organization (CDMO) model." Hyemin Heo, a researcher at Kiwoom Securities, explained the rationale for maintaining the target price by saying, "One-off cost issues have disappeared, and revenue contribution from the fifth plant as well as the acquisition of the U.S. plant will serve as triggers for a performance upgrade." This reaffirms that Samsung Biologics remains the most reliable investment alternative amid external uncertainties.

The key investment point attracting market attention is the benefit Samsung Biologics stands to gain from the implementation of the U.S. Biosecure Act. As the U.S.-China conflict forces global pharmaceutical companies to reduce their dependence on China, Samsung Biologics-equipped with proven production capabilities-is expected to benefit from a 'trickle-down effect' as orders are redirected to the company.

An industry insider analyzed, "2026 will be the first year when the global bio supply chain is restructured around a 'China-Free' paradigm. As the position of its competitor, WuXi Biologics of China, becomes more constrained, Samsung Biologics' bargaining power and market share are structurally bound to increase."

To seize this opportunity, Samsung Biologics has made a bold move by acquiring the Rockville plant in the United States. Sales from this plant, which will begin to be recognized from the second quarter, will meet the needs of clients requiring local production in the U.S., positioning it as a strategic hub to mitigate geopolitical risks. NH Investment & Securities estimates that the U.S. plant will contribute an additional 7-8% to this year's revenue.

In addition, the fifth plant, which will see increased utilization this year, and the sixth plant, expected to break ground this year, guarantee overwhelming production capacity. The securities industry interprets the company's sales growth guidance for this year (15-20%) as a 'conservative figure,' and anticipates that both performance and valuation will rise together, depending on the pace at which orders shift away from China.

This content was produced with the assistance of AI translation services.